The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.La presente invención se refiere a un anticuerpo monoclonal aislado, o una porción del mismo de fijación al antígeno, que se fija a un LAG-3 humano, caracterizado porque las regiones CDR1, CDR2 y CDR3 de cadena pesada comprende las secuencias de aminoácidos de las SEC ID Nos: 15, 16 y 17, respectivamente y en donde las regiones CDR1, CDR2 y CDR3 de cadena ligera comprende las secuencias de aminoácidos de las SEX ID Nos: 18, 19 y 20, respectivamente.
